RY 169.51 -1.1719% SHOP 175.85 -3.2036% TD 85.4 -0.187% ENB 59.6 -1.715% BN 84.78 -1.4873% TRI 250.65 2.1186% CNQ 43.69 0.9007% CP 110.72 -0.5926% CNR 146.88 0.7891% BMO 142.84 -0.6054% BNS 72.34 -0.0829% CSU 4896.4902 0.1981% CM 87.07 -0.9668% MFC 45.08 6.5217% ATD 71.13 -0.6425% NGT 68.13 0.9932% TRP 64.42 -1.2872% SU 56.73 -0.0176% WCN 266.69 -0.146% L 176.74 -1.5157%
Last update at 2025-02-20T19:00:00Z
Eli Lilly and Company (LLY) Slid as its GLP-1 Revenue Missed Expectations
Wed 19 Feb 25, 03:14 PMWhat Top-Performing Healthcare Funds Are Buying Now
Wed 19 Feb 25, 07:30 AMDeutsche Bank upgrades Gilead on its HIV treatment franchise
Tue 18 Feb 25, 05:36 PMLilly to participate in TD Cowen's 45th Annual Health Care Conference
Tue 18 Feb 25, 03:00 PMCan Eli Lilly and Company (NYSE:LLY) Maintain Its Strong Returns?
Tue 18 Feb 25, 02:00 PMWhy Eli Lilly and Company (LLY) Is the Best Drug Stock to Buy Now
Mon 17 Feb 25, 07:56 AMInvestor Reveals 5 Stocks That Helped Him Retire at 55–'Now I Live The Good Life'
Sun 16 Feb 25, 10:30 PMThink Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
Sat 15 Feb 25, 12:30 PMSteve Mandel's Strategic Moves: A Closer Look at Eli Lilly and Co's 4.49% Portfolio Impact
Fri 14 Feb 25, 11:28 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 6806.40M | 6155.50M | 7229.90M | 5265.90M | 3680.10M |
| Minority interest | - | - | 183.60M | 92.20M | 1080.40M |
| Net income | 6244.80M | 5581.70M | 6193.70M | 4637.90M | 3232.00M |
| Selling general administrative | 6440.40M | 6431.60M | 6121.20M | 6213.80M | 5975.10M |
| Selling and marketing expenses | - | - | - | 6213.80M | 5975.10M |
| Gross profit | 21911.60M | 21005.60M | 19056.50M | 17598.30M | 16811.60M |
| Reconciled depreciation | 1522.50M | 1547.60M | 1323.90M | 1232.60M | 1609.00M |
| Ebit | 7127.30M | 6357.10M | 6058.00M | 4974.30M | 8036.10M |
| Ebitda | 9433.50M | 8739.10M | 7641.20M | 6604.70M | 9645.10M |
| Depreciation and amortization | 2306.20M | 2382.00M | 1583.20M | 1630.40M | 1609.00M |
| Non operating income net other | -320.90000M | - | - | 291.60M | 74.80M |
| Operating income | 7127.30M | 6357.10M | 6058.00M | 4974.30M | 6186.80M |
| Other operating expenses | 20261.00M | 20770.30M | 17690.20M | 16530.00M | 15708.00M |
| Interest expense | 331.60M | 339.80M | 359.60M | 400.60M | 272.10M |
| Tax provision | 561.60M | 573.80M | 1036.20M | 628.00M | 563.70M |
| Interest income | 268.80M | 314.40M | 326.60M | 80.40M | 161.30M |
| Net interest income | -268.80000M | -314.40000M | -326.60000M | -320.20000M | -110.80000M |
| Extraordinary items | - | 0.00000M | 0.00000M | 3680.50M | -93.90000M |
| Non recurring | 244.60M | - | - | 815.20M | 2465.90M |
| Other items | - | - | - | - | - |
| Income tax expense | 561.60M | 573.80M | 1036.20M | 628.00M | 529.50M |
| Total revenue | 28541.40M | 28318.40M | 24539.80M | 22319.50M | 21493.30M |
| Total operating expenses | 13631.20M | 13457.50M | 12206.90M | 11808.80M | 11026.30M |
| Cost of revenue | 6629.80M | 7312.80M | 5483.30M | 4721.20M | 4681.70M |
| Total other income expense net | -320.90000M | -201.60000M | 1171.90M | 291.60M | -2105.20000M |
| Discontinued operations | - | - | - | 3680.50M | 81.40M |
| Net income from continuing ops | 6244.80M | 5581.70M | 6193.70M | 4637.90M | 3232.00M |
| Net income applicable to common shares | 6244.80M | 5581.70M | 6193.70M | 8318.40M | 3232.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 64006.30M | 49489.80M | 48806.00M | 46633.10M | 39286.10M |
| Intangible assets | 6906.60M | 7206.60M | 7691.90M | 7450.00M | 6618.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 5690.30M | 2954.10M | 2530.60M | 2871.50M | 2538.90M |
| Total liab | 53142.60M | 38714.40M | 39651.20M | 40807.90M | 36587.00M |
| Total stockholder equity | 10771.90M | 10649.80M | 8979.20M | 5641.60M | 2606.90M |
| Deferred long term liab | - | 87.30M | - | - | 2187.50M |
| Other current liab | 13940.70M | 13706.50M | 3027.50M | 2750.30M | 2189.40M |
| Common stock | 593.60M | 594.10M | 596.30M | 598.20M | 598.80M |
| Capital stock | 593.60M | 594.10M | 596.30M | 598.20M | 598.80M |
| Retained earnings | 10312.30M | 10042.60M | 8958.50M | 7830.20M | 4920.40M |
| Other liab | - | 6130.40M | 8674.20M | 11029.00M | 10481.40M |
| Good will | 4939.70M | 4073.00M | 3892.00M | 3766.50M | 3679.40M |
| Other assets | - | 7129.90M | 6380.00M | 9274.00M | 4748.30M |
| Cash | 2818.60M | 2067.00M | 3818.50M | 3657.10M | 2337.50M |
| Cash and equivalents | - | 2067.00M | 3818.50M | 3657.10M | 2337.50M |
| Total current liabilities | 27293.20M | 17138.20M | 15052.70M | 12481.60M | 11775.20M |
| Current deferred revenue | 14508.60M | - | 8816.30M | 8115.90M | 6681.20M |
| Net debt | 22406.70M | 14171.60M | 13066.20M | 12938.20M | 13466.40M |
| Short term debt | 6904.50M | 1501.10M | 1538.30M | 8.70M | 1499.30M |
| Short long term debt | 6904.50M | 1501.10M | 1538.30M | 8.70M | 1499.30M |
| Short long term debt total | 25225.30M | 16238.60M | 16884.70M | 16595.30M | 15803.90M |
| Other stockholder equity | 4193.00M | 3857.70M | 3767.50M | 3709.60M | 3611.30M |
| Property plant equipment | - | 10144.00M | 8985.10M | 8681.90M | 7872.90M |
| Total current assets | 25727.00M | 18034.50M | 18452.40M | 17462.10M | 13709.60M |
| Long term investments | 3052.20M | 2901.80M | 3212.60M | 2966.80M | 1962.40M |
| Net tangible assets | - | -629.80000M | -4014.80000M | -5574.90000M | -7690.50000M |
| Short term investments | 109.10M | 144.80M | 90.10M | 24.20M | 101.00M |
| Net receivables | 11336.20M | 8558.90M | 8127.20M | 6929.00M | 5541.50M |
| Long term debt | 18320.80M | 14737.50M | 15346.40M | 16586.60M | 13817.90M |
| Inventory | 5772.80M | 4309.70M | 3886.00M | 3980.30M | 3190.70M |
| Accounts payable | 2598.80M | 1930.60M | 1670.60M | 1606.70M | 1405.30M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 91.80M | 125.60M | - | - | 92.20M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4327.00000M | -3844.60000M | -4343.10000M | -6496.40000M | -6523.60000M |
| Additional paid in capital | 7250.40M | - | - | - | - |
| Common stock total equity | - | 594.10M | - | 598.20M | 598.80M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 10042.60M | - | - | 4920.40M |
| Treasury stock | -44.20000M | - | -52.70000M | -55.70000M | -60.80000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4989.90M | 4337.00M | 4082.70M | 3475.40M | 2339.10M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 38279.30M | 31455.30M | 30353.60M | 29171.00M | 25576.50M |
| Capital lease obligations | - | - | - | - | 486.70M |
| Long term debt total | - | 14737.50M | 15346.40M | 16586.60M | 13817.90M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -7152.70000M | -244.00000M | -166.00000M | 516.70M | 456.20M |
| Change to liabilities | - | 1678.30M | -664.10000M | 1271.30M | -699.00000M |
| Total cashflows from investing activities | -7152.70000M | -3762.90000M | -2867.50000M | -2258.90000M | -8082.90000M |
| Net borrowings | - | -62.00000M | 501.40M | 291.60M | 4685.40M |
| Total cash from financing activities | 3495.60M | -5406.70000M | -4131.30000M | -3137.10000M | -2324.50000M |
| Change to operating activities | - | -793.50000M | 1515.40M | -457.10000M | -602.30000M |
| Net income | 5240.40M | 6244.80M | 5581.70M | 6193.70M | 8318.40M |
| Change in cash | 751.60M | -1751.50000M | 161.40M | 1319.60M | -5660.70000M |
| Begin period cash flow | 2067.00M | 3818.50M | 3657.10M | 2337.50M | 7998.20M |
| End period cash flow | 2818.60M | 2067.00M | 3818.50M | 3657.10M | 2337.50M |
| Total cash from operating activities | 4240.10M | 7084.40M | 7260.70M | 6499.60M | 4836.60M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1527.30M | 1522.50M | 1547.60M | 1323.90M | 1232.60M |
| Other cashflows from investing activities | -2532.10000M | -1163.30000M | 24.30M | 102.80M | -7505.20000M |
| Dividends paid | 4069.30M | 3535.80M | 3086.80M | 2687.10M | 2409.80M |
| Change to inventory | -1425.00000M | -599.70000M | -235.90000M | -533.40000M | -258.70000M |
| Change to account receivables | -2451.00000M | -299.60000M | -1278.30000M | -1350.00000M | -127.20000M |
| Sale purchase of stock | -750.00000M | -1500.00000M | -1250.00000M | -500.00000M | -4400.00000M |
| Other cashflows from financing activities | -335.00000M | 1189.10M | -295.90000M | -241.60000M | -200.10000M |
| Change to netincome | - | -668.40000M | 1154.00M | -270.60000M | 653.30M |
| Capital expenditures | 7392.10M | 2484.00M | 1873.20M | 2029.10M | 1353.50M |
| Change receivables | - | -299.60000M | - | - | -127.20000M |
| Cash flows other operating | - | -793.50000M | - | - | -602.30000M |
| Exchange rate changes | - | - | - | - | -89.90000M |
| Cash and cash equivalents changes | - | -1583.90000M | - | - | -5660.70000M |
| Change in working capital | -3055.00000M | -14.50000M | -1022.60000M | -747.40000M | -1687.20000M |
| Stock based compensation | 628.50M | 371.10M | 342.80M | 308.10M | 312.40M |
| Other non cash items | 2239.90M | 1145.70M | 1613.50M | -444.20000M | -3402.00000M |
| Free cash flow | -3152.00000M | 4600.40M | 5387.50M | 4470.50M | 3483.10M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company |
5.62 0.65% | 872.67 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
1.67 1.06% | 159.56 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
2.65 1.34% | 200.00 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
1.50 1.75% | 87.09 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
| AZN AstraZeneca PLC ADR |
0.78 1.06% | 74.59 | 38.69 | 16.31 | 4.67 | 5.46 | 5.20 | 17.74 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Lilly Corporate Center, Indianapolis, IN, United States, 46285
| Name | Title | Year Born |
|---|---|---|
| Mr. David A. Ricks | Chairman, CEO & Pres | 1968 |
| Ms. Anat Ashkenazi | Sr. VP & CFO | 1972 |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs | 1974 |
| Mr. Diogo Rau | Sr. VP & Chief Information and Digital Officer | NA |
| Mr. Jacob S. Van Naarden | Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology | 1985 |
| Mr. Donald A. Zakrowski | Chief Accounting Officer & VP of Fin. | NA |
| Mr. Martin Bott MIBS | VP of Fin. & Special Projects | 1963 |
| Ms. Anat Hakim J.D. | Sr. VP, Gen. Counsel & Sec. | 1969 |
| Mr. Alonzo Weems | Sr. VP and Chief Ethics & Compliance Officer | NA |
| Ms. Leigh Ann Pusey | Sr. VP of Corp. Affairs & Communications | 1963 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...